Guizhou bailing Tangning Tongluo capsule obtained clinical research approval

Guizhou bailing water test diabetes research and development started last year In April 2013, the company paid 5 million yuan to Yang Guoshun and Yang Ailong to purchase the Miao medicine formula According to the contract signed by both parties, Guizhou bailing has the right to buy out the secret recipe at one time, with the maximum purchase price not exceeding 100 million yuan The research and development of Guizhou bailing's diabetes medicine has come a long way since it spent billion yuan to buy the secret recipe of diabetes, was questioned by all parties in the market, and obtained obvious hypoglycemic effect from animal experiments Because diabetes is a worldwide problem and there is no cure drug, the company's move has been widely questioned by the market However, Guizhou bailing later announced that the Institute of medicinal plants, Chinese Academy of Medical Sciences, through the "experiment on the effect of Tangning Tongluo Capsule on DB / DB spontaneous diabetic mice", initially proved that Tangning Tongluo capsule has a better hypoglycemic effect, the high-dose group is slightly better than the dimethylbiguanidine group, and has a significant improvement on glucose tolerance Up to now, Guizhou bailing Tangning Tongluo capsule has obtained clinical approval, and the company's diabetes research has entered the substantive stage of human body test However, the reporter noted that when the drug entered the human trial stage, it did not mean that it would definitely pass the new drug application The company gave a risk warning in the announcement Since last year, listed companies have sent out innovative dividend ideas Quantum high tech has distributed Guiling cream to shareholders and sesame milk to Southern food Today, Guizhou bailing has put forward a special plan to repay shareholders According to the announcement, in order to return the majority of investors and pay attention to the health of shareholders, the company's shareholders can first register to participate in the clinical trial, and the relevant test fees and drug fees are exempted, and the registration time is up to March 19, 2014 Guizhou bailing dongmi niumin told the daily economic news that this was mainly because the company had received a lot of calls from investors who wanted to try the new drug But at present, the company is unable to provide it, so it has come up with a way for clinical volunteers to achieve two goals with one stone and give back to investors Niumin also revealed that with the issuance of clinical approval documents from Guizhou Provincial Drug Administration, the company will immediately start human clinical trials The shareholders who participate in the registration, regardless of the size of the equity and the registration sequence, will be registered first, and the number of participants will be determined after the clinical scheme is determined So what is the company's confidence in the clinical trials of Tangning Tongluo capsule? Niu Min said that the new drug has been tested in animals and has achieved good hypoglycemic effect The company has accumulated rich experience in the safety and effectiveness of drug use, and is confident in human clinical trials But he also said that all experiments were risky How to consider the risk of shareholders' participation in clinical trials? Niumin believed that, first of all, the clinical trial was approved by Guizhou food and drug administration, and all procedures were legal Secondly, before the clinical trial, the company will fully communicate with the shareholders to ensure the voluntary nature of both parties In addition, all procedures of the company in clinical trials will be completed in accordance with legal procedures to ensure the rigor of the trials.